Pulmonary Arterial Hypertension Treatment Market

Pulmonary Arterial Hypertension Treatment Market: Lack of Treatment Awareness, Inadequate R&D, & Frequent Drug Rejection Post Clinical Trial to Hamper Growth: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

Ask The Analyst Customization Available Request Methodology

Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.

According to Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), the global prevalence of pulmonary arterial hypertension treatment market is projected to be 100,000 – 200,000—which accounts for 15 - 50 patients per million of the population. Expert analysis into the subject has reveals that due to the rarity of the disease and the complexity of diagnosing it, only a small fraction of patients with PAH are being treated. Due to which, the Global Pulmonary Arterial Hypertension Treatment market is anticipated to grow at a sluggish CAGR of 2.5% over the forecast period 2018-2028.

Endothelin Receptor Antagonists (ERAs) to lead the Market among Drugs; SGC Stimulators to Capture Market by the End of 2028 Owing to Drug Effectiveness

Pulmonary-Arterial-Hypertension-Treatment-Market.jpg

According to expert analysis, the global pulmonary arterial hypertension treatment market is anticipated to grow at a steady rate. Based on drug type, the global pulmonary arterial hypertension treatment market is segmented into vasodilators, Phosphodiesterase 5 (PDE 5) inhibitors, Endothelin receptor Antagonists (ERA), Soluble guanylate cyclase (SGC) stimulator with ERAs accounting for the highest market share in terms of value. However, SGC stimulator drug- is expected to witness relatively higher growth rates in terms of value in the global pulmonary arterial hypertension treatment market, due to its positive results. According to research Riociguat is the first SGC stimulator that has entered clinical development- showing significantly results in treating pulmonary vascular haemodynamics and increases exercise ability in patients with PAH.

Lack of Awareness, Slow Drug R&D, and Unsuccessful Clinical Trials Restraining the Growth of Global Pulmonary Arterial Hypertension Treatment Market

Rising prevalence of pulmonary arterial hypertension has witnessed increased adoption of medicinal treatment of PAH, healthcare spending, rise in awareness, and huge drug pipeline. However, several factors have hampered the growth of global pulmonary arterial hypertension treatment market.

Currently, several forms of medication in the global prevalence of pulmonary arterial hypertension treatment market are adopted by people with PAH, but unfortunately no treatment has significantly improved survival. For instance, Ruvise (imatinib)-used for adults as add-on therapy for the treatment PAH, is continually questioned for its efficacy. Treatment with Ruvise should only be initiated in patients who are not showing signs of rapid disease progression. Ruvise has been studied only in combination with two or more conventional PAH-specific therapies. Efficacy has been shown in patients suffering from idiopathic PAH, heritable PAH and in PAH associated with connective tissue disease. Medical research has also shown an unexplained higher risk of subdural haemorrhage associated with imatinib use.

Additionally, slow productivity of R&D in the global pulmonary arterial hypertension treatment market owing to high diagnosis and treatment cost, termination of drugs by major players during clinical trials, unawareness about presence of pulmonary arterial hypertension among patients are some of the factors which are hampering the growth of this market. Lastly, expiry of patents of major PAH drugs will lead to generic versions of these drugs being sold at 60% to 70% lower prices than that of the present branded drugs- projected to pose a challenge for the growth the global pulmonary arterial hypertension treatment market.

Market experts at Future Market Insights (FMI) offer a 10-year forecast on the global pulmonary arterial hypertension treatment market with a primary objective to offer actionable insights, updates and, information related to market opportunities in the global pulmonary arterial hypertension treatment market- which in terms of revenue is anticipated to grow at a slow CAGR of 2.5% during the forecast period, 2018–2028. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global pulmonary arterial hypertension treatment market are explored and presented in the report.

The global market for Pulmonary arterial hypertension treatment market is expected to witness to grow owing to rising prevalence of pulmonary arterial hypertension disease, increasing adoption of treatment and healthcare spending, huge drug pipeline, and external partnerships in research driving new treatment formulations. These factors are also anticipated to give rise to investment opportunities to key players in the global pulmonary arterial hypertension treatment market.

A key feature of this report- mostly overlooked in other reports is the analysis of key segments in terms of absolute dollar opportunity- which is absolutely critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by pulmonary arterial hypertension treatment market. To understand key segments in terms of their growth and performance in the global pulmonary arterial hypertension treatment market, FMI has developed a market attractiveness index to help providers identify existing market opportunities.

Revenue from the pulmonary arterial hypertension treatment market in North America is the most dominating due to increase awareness and improvement in healthcare system. To understand and assess opportunities in this market, the report offers the market forecast on the basis of type into the drug type, distribution channel, and regions. The report provides analysis of the global Pulmonary arterial hypertension treatment market in terms of market value (US$ Mn).  

The global pulmonary arterial hypertension treatment market is segmented on the basis of drug type into:

  • Vasodilators

  • Phosphodiesterase 5 (PDE 5) inhibitors

  • Endothelin receptor Antagonists (ERA)

  • Soluble guanylate cyclase (SGC) stimulator

The report also has a ‘market dynamics’ section, wherein FMI’s analysis key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global pulmonary arterial hypertension treatment market.

The report analyses the market on the basis of the distribution channel and presents an in-depth analysis of:

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

Next up, the report analyses the market on the basis of regions:

  • North America

    • U.S.

    • Canada

  • Latin America

    • Brazil

    • Mexico

    • Rest of Latin America

  • Western Europe

    • UK

    • France

    • Germany

    • Italy

    • Spain

    • BENELUX countries

    • Nordic Countries

    • Rest of Western Europe

  • Eastern Europe

    • Russia

    • Poland

    • Rest of Eastern Europe

  • Asia Pacific

    • India

    • Australia & New Zealand

    • Rest of APECJ

  • China

  • Japan

  • Middle East & Africa (MEA)

    • GCC Countries

    • South Africa

    • Rest of MEA

In addition, FMI has also considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global pulmonary arterial hypertension treatment market.

In the final section of the report, a ‘competitive landscape’ has been included to provide a dashboard view of key companies operating in the global pulmonary arterial hypertension treatment market. The companies analysed are GlaxoSmithKline plc, Eli Lilly and Company, Pfizer Inc., Actelion Inc., (Johnson & Johnson Services, Inc.), United Therapeutic Corporation, SteadyMed Ltd., Gilead Sciences, Inc., Teva Pharmaceuticals Inc., and Bayer AG to name a few. This section is primarily designed to provide a detailed comparative assessment of key providers specific to a market segment in the pulmonary arterial hypertension treatment market and the potential players. This section also includes long- and short-term market strategies and SWOT analysis of the main players operational in the global pulmonary arterial hypertension treatment market.

Pulmonary Arterial Hypertension Treatment Market Reports - Table of Contents

1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. Hidden Facts

1.4. FMI Analysis and Recommendations

1.5. Wheel of Fortune

2. Market Introduction

2.1. Evolution

2.2. Market Definition

2.3. Market Taxonomy

3. Pulmonary Arterial Hypertension Treatment Market Analysis

3.1. Overview of Pulmonary Arterial Hypertension Treatments

3.2. Macro-Economic Factors

4. Market Background

4.1. Value Chain

4.2. Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunity Analysis

4.3. Regulatory Scenario

4.4. Pipeline Assessment

4.5. Reimbursement Scenario

5. Macroeconomic Assumptions

6. Global Economic Outlook

6.1. Gross Domestic Product by Region & Country, 2016 – 2021

6.2. Disease epidemiology Analysis

7. North America Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028

7.1. Introduction

7.2. Regional Market Trends

7.3. Historical Market Size (US$ Mn) Analysis By Country, 2013–2017

7.3.1. U.S.

7.3.2. Canada

7.4. Market Size (US$ Mn) Forecast By Country, 2018–2028

7.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017

7.5.1. Vasodilators

7.5.2. Endothelin receptor antagonists

7.5.3. PDE-5

7.5.4. Soluble guanylate cyclase (SGC) stimulator

7.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028

7.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017

7.7.1. Hospitals

7.7.2. Retail Pharmacies

7.7.3. Online Pharmacies

7.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028

7.9. Market Attractiveness Analysis

7.9.1. By Country

7.9.2. By Drug Class

7.9.3. By Distribution Channel

7.10.Key Market Participants – Intensity Mapping

7.11.Drivers and Restraints – Impact Analysis

8. Latin America Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028

8.1. Introduction

8.2. Regional Market Trends

8.3. Historical Market Size (US$ Mn) Trends Analysis By Country, 2013–2017

8.3.1. Argentina

8.3.2. Brazil

8.3.3. Mexico

8.3.4. Rest of Latin America

8.4. Market Size (US$ Mn) Forecast By Country, 2018–2028

8.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017

8.5.1. Vasodilators

8.5.2. Endothelin receptor antagonists

8.5.3. PDE-5

8.5.4. Soluble guanylate cyclase (SGC) stimulator

8.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028

8.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017

8.7.1. Hospitals

8.7.2. Retail Pharmacies

8.7.3. Online Pharmacies

8.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028

8.9. Market Attractiveness Analysis

8.9.1. By Country

8.9.2. By Drug Class

8.9.3. By Distribution Channel

8.10.Key Market Participants – Intensity Mapping

8.11.Drivers and Restraints – Impact Analysis

9. Western Europe Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028

9.1. Introduction

9.2. Regional Market Trends

9.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017

9.3.1. Germany

9.3.2. U.K.

9.3.3. France

9.3.4. Italy

9.3.5. Spain

9.3.6. Nordic Countries

9.3.7. BENELUX

9.3.8. Rest of Western Europe

9.4. Market Size (US$ Mn) Forecast By Country, 2018–2028

9.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017

9.5.1. Vasodilators

9.5.2. Endothelin receptor antagonists

9.5.3. PDE-5

9.5.4. Soluble Guanylate Cyclase (SGC) stimulator

9.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028

9.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017

9.7.1. Hospitals

9.7.2. Retail Pharmacies

9.7.3. Online Pharmacies

9.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028

9.9. Market Attractiveness Analysis

9.9.1. By Country

9.9.2. By Drug Class

9.9.3. By Distribution Channel

9.10.Key Market Participants – Intensity Mapping

9.11.Drivers and Restraints – Impact Analysis

10. Eastern Europe Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028

10.1.Introduction

10.2.Regional Market Trends

10.3.Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017

10.3.1. Russia

10.3.2. Poland

10.3.3. Rest of Eastern Europe

10.4.Market Size (US$ Mn) Forecast By Country, 2018–2028

10.5.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017

10.5.1. Vasodilators

10.5.2. Endothelin receptor antagonists

10.5.3. PDE-5

10.5.4. Soluble guanylate cyclase (SGC) stimulator

10.6.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028

10.7.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017

10.7.1. Hospitals

10.7.2. Retail Pharmacies

10.7.3. Online Pharmacies

10.8.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028

10.9.Market Attractiveness Analysis

10.9.1. By Country

10.9.2. By Drug Class

10.9.3. By Distribution Channel

10.10.Key Market Participants – Intensity Mapping

10.11.Drivers and Restraints – Impact Analysis

11. Asia Pacific Excluding China & Japan Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028

11.1.Introduction

11.2.Regional Market Trends

11.3.Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017

11.3.1. India

11.3.2. Australia and New Zealand

11.3.3. ASEAN Countries

11.3.4. Rest of Asia Pacific

11.4.Market Size (US$ Mn) Forecast By Country, 2018–2028

11.5.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017

11.5.1. Vasodilators

11.5.2. Endothelin receptor antagonists

11.5.3. PDE-5

11.5.4. Soluble guanylate cyclase (SGC) stimulator

11.6.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028

11.7.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017

11.7.1. Hospitals

11.7.2. Retail Pharmacies

11.7.3. Online Pharmacies

11.8.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028

11.9.Market Attractiveness Analysis

11.9.1. By Country

11.9.2. By Drug Class

11.9.3. By Distribution Channel

11.10.Key Market Participants – Intensity Mapping

11.11.Drivers and Restraints – Impact Analysis

12. China Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028

12.1.Introduction

12.2.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017

12.2.1. Vasodilators

12.2.2. Endothelin receptor antagonists

12.2.3. PDE-5

12.2.4. Soluble guanylate cyclase (SGC) stimulator

12.3.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028

12.4.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017

12.4.1. Hospitals

12.4.2. Retail Pharmacies

12.4.3. Online Pharmacies

12.5.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028

12.6.Market Attractiveness Analysis

12.6.1. By Drug Class

12.6.2. By Distribution Channel

12.7.Key Market Participants – Intensity Mapping

12.8.Drivers and Restraints – Impact Analysis

13. Japan Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028

13.1.Introduction

13.2.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017

13.2.1. Vasodilators

13.2.2. Endothelin receptor antagonists

13.2.3. PDE-5

13.2.4. Soluble guanylate cyclase (SGC) stimulator

13.3.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028

13.4.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017

13.4.1. Hospitals

13.4.2. Retail Pharmacies

13.4.3. Online Pharmacies

13.5.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028

13.6.Market Attractiveness Analysis

13.6.1. By Drug Class

13.6.2. By Distribution Channel

13.7.Key Market Participants – Intensity Mapping

13.8.Drivers and Restraints – Impact Analysis

14. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028

14.1.Introduction

14.2.Regional Market Trends

14.3.Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2017

14.3.1. GCC Countries

14.3.2. South Africa

14.3.3. Rest of MEA

14.4.Market Size (US$ Mn) Forecast By Country, 2018–2028

14.5.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017

14.5.1. Vasodilators

14.5.2. Endothelin receptor antagonists

14.5.3. PDE-5

14.5.4. Soluble guanylate cyclase (SGC) stimulator

14.6.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028

14.7.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2017

14.7.1. Hospitals

14.7.2. Retail Pharmacies

14.7.3. Online Pharmacies

14.8.Market Size (US$ Mn) Forecast By Distribution Channel, 2018–2028

14.9.Market Attractiveness Analysis

14.9.1. By Country

14.9.2. By Drug Class

14.9.3. By Distribution Channel

14.10.Key Market Participants – Intensity Mapping

14.11.Drivers and Restraints – Impact Analysis

15. Forecast Factors: Relevance and Impact

16. Forecast Assumptions

17. Competition Landscape

17.1.Market Structure

17.2.Competition Intensity Mapping By Market Taxonomy

17.3.Competition Dashboard

17.4. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

17.4.1. United Therapeutics Ltd.

17.4.1.1. Overview

17.4.1.2. Key Financials

17.4.1.3. Product and Application Portfolio

17.4.1.4. Recent Developments

17.4.1.5. Strategy

17.4.1.6. SWOT Analysis

17.4.2. Bayer AG

17.4.2.1. Overview

17.4.2.2. Key Financials

17.4.2.3. Product and Application Portfolio

17.4.2.4. Recent Developments

17.4.2.5. Strategy

17.4.2.6. SWOT Analysis

17.4.3. Actelion Ltd.

17.4.3.1. Overview

17.4.3.2. Key Financials

17.4.3.3. Product and Application Portfolio

17.4.3.4. Recent Developments

17.4.3.5. Strategy

17.4.3.6. SWOT Analysis

17.4.4. Pfizer, Inc

17.4.4.1. Overview

17.4.4.2. Key Financials

17.4.4.3. Product and Application Portfolio

17.4.4.4. Recent Developments

17.4.4.5. Strategy

17.4.4.6. SWOT Analysis

17.4.5. Gilead Sciences, Inc.

17.4.5.1. Overview

17.4.5.2. Key Financials

17.4.5.3. Product and Application Portfolio

17.4.5.4. Recent Developments

17.4.5.5. Strategy

17.4.5.6. SWOT Analysis

17.4.6. GlaxoSmithKline plc

17.4.6.1. Overview

17.4.6.2. Key Financials

17.4.6.3. Product and Application Portfolio

17.4.6.4. Recent Developments

17.4.6.5. Strategy

17.4.6.6. SWOT Analysis

17.4.7. Teva Pharmaceuticals Inc.

17.4.7.1. Overview

17.4.7.2. Key Financials

17.4.7.3. Product and Application Portfolio

17.4.7.4. Recent Developments

17.4.7.5. Strategy

17.4.7.6. SWOT Analysis

17.4.8. Eli Lilly and Company

17.4.8.1. Overview

17.4.8.2. Key Financials

17.4.8.3. Product and Application Portfolio

17.4.8.4. Recent Developments

17.4.8.5. Strategy

17.4.8.6. SWOT Analysis

17.4.9. Steady Med Ltd.

17.4.9.1. Overview

17.4.9.2. Key Financials

17.4.9.3. Product and Application Portfolio

17.4.9.4. Recent Developments

17.4.9.5. Strategy

17.4.9.6. SWOT Analysis

17.4.10. Johnson & Johnson Services, Inc

17.4.10.1. Overview

17.4.10.2. Key Financials

17.4.10.3. Product and Application Portfolio

17.4.10.4. Recent Developments

17.4.10.5. Strategy

17.4.10.6. SWOT Analysis

18. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Region

18.1.Introduction / Key Findings

18.2.Historical Market Size (US$ Mn) By Region

18.2.1. North America

18.2.2. Western Europe

18.2.3. Eastern Europe

18.2.4. Latin America

18.2.5. Asia Pacific Excluding China & Japan

18.2.6. China

18.2.7. Japan

18.2.8. Middle East and Africa

18.3.Market Size (US$ Mn) Forecast By Region

18.3.1. North America

18.3.2. Western Europe

18.3.3. Eastern Europe

18.3.4. Latin America

18.3.5. Asia Pacific Excluding China & Japan

18.3.6. China

18.3.7. Japan

18.3.8. Middle East and Africa

18.4.Market Attractiveness Analysis By Region

19. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Drug Class

19.1.Introduction

19.2.Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2017

19.2.1. Vasodilators

19.2.2. Endothelin receptor antagonists

19.2.3. PDE-5

19.2.4. Soluble guanylate cyclase (SGC) stimulator

19.3.Market Size (US$ Mn) and Volume Forecast By Drug Class, 2018–2028

19.4.Key Trends / Developments

19.5.Market Attractiveness Analysis By Drug Class Type

20. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channels

20.1.Introduction

20.2.Historical Market Size (US$ Mn) Analysis By Distribution Channels , 2012-2016

20.2.1. Hospitals

20.2.2. Retail Pharmacies

20.2.3. Online Pharmacies

20.3.Market Size (US$ Mn) and Forecast By Distribution Channels , 2017-2027

20.3.1. Hospitals

20.3.2. Retail Pharmacies

20.3.3. Online Pharmacies

20.4.Key Trends / Developments

20.5.Market Attractive Analysis By Distribution Channels

21. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2013–2017 and Forecast 2018–2028

21.1.Global Volume Analysis

21.2.Market Size and Y-o-Y Growth

21.3.Absolute $ Opportunity

22. Assumptions and Acronyms Used

23. Research Methodology

Pulmonary Arterial Hypertension Treatment Market Reports - List of Tables

Table 01: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 03: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 04: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 05: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 06: North America Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 07: Latin America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 08: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 09: Latin America Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 10: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 11: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 12: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 13: Western Europe Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 14: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 15: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 16: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 17: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 18: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 19: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 20: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 21: APECJ Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 22: China Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 23: China Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 24: China Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 25: Japan Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 26: Japan Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 27: Japan Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 28: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 29: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 30: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 31: MEA Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 32: Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Forecast By Region, 2013-2028

Table 33: Global Pulmonary Arterial Hypertension Treatment Market Size Value (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028 , By Drug Type

Table 34: Global Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

Table 01: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 03: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 04: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 05: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 06: North America Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 07: Latin America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 08: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 09: Latin America Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 10: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 11: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 12: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 13: Western Europe Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 14: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 15: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 16: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 17: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 18: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 19: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 20: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 21: APECJ Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 22: China Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 23: China Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 24: China Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 25: Japan Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 26: Japan Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 27: Japan Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 28: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2013–2017 and Forecast 2018-2028  By Country

Table 29: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Drug Type

Table 30: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2013–2017 and Forecast 2018-2028  By Distribution Channel

Table 31: MEA Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 32: Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Forecast By Region, 2013-2028

Table 33: Global Pulmonary Arterial Hypertension Treatment Market Size Value (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028 , By Drug Type

Table 34: Global Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

Pulmonary Arterial Hypertension Treatment Market Reports - List of Figures

Figure 01: Global Pulmonary Arterial Hypertension Treatment Market Value Share 2018E, By Region

Figure 02: Global Pulmonary Arterial Hypertension Treatment Market Value Share, By Drug Class

Figure 03: Global Healthcare Expenditure in US$ Tn (2013–2020)

Figure 04: North America Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2013–2017

Figure 05: North America Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 06: U.S. Pulmonary Arterial Hypertension Treatment, Market Size (US$ Mn) Analysis, 2013–2017 

Figure 07: U.S. Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 08: Canada Pulmonary Arterial Hypertension Treatment, Market Size (US$ Mn) Analysis, 2013–2017 

Figure 09: Canada Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 10: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By Vasodilators

Figure 11: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By Vasodilators 

Figure 12: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By ERA

Figure 13: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By ERA

Figure 14: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By PDE-5

Figure 15: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By PDE-5

Figure 16: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By sGC stimulator 

Figure 17: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By sGC stimulator 

Figure 18: North America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2018-2028

Figure 19: North America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2018-2028 

Figure 20: North America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2028  

Figure 21: Latin America Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2013–2017

Figure 22: Latin America Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 23: Brazil Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 24: Brazil Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 25: Mexico Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 26: Mexico Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 27: Argentina Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 28: Argentina Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 29: Rest of LATAM Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 30: Rest of LATAM Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 31: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By Vasodilators

Figure 32: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By Vasodilators 

Figure 33: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By ERA

Figure 34: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By ERA

Figure 35: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By PDE-5

Figure 36: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By PDE-5

Figure 37: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By sGC stimulator 

Figure 38: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By sGC stimulator 

Figure 39: Latin America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2018-2028

Figure 40: Latin America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2018-2028 

Figure 41: Latin America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2028  

Figure 42: Western Europe Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2013–2017

Figure 43: Western Europe Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 44: Germany Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 45: Germany Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 46: U.K. Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 47: U.K. Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 48: France Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 49: France Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 50: Italy Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 51: Italy Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 52: Spain Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 53: Spain Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 54: Nordic Countries Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 55: Nordic Countries Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 56: BENELUX Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 57: BENELUX Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 58: Rest of Western Europe Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 59: Rest of Western Europe Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 60: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By Vasodilators

Figure 61: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By Vasodilators 

Figure 62: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By ERA

Figure 63: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By ERA

Figure 64: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By PDE-5

Figure 65: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By PDE-5

Figure 66: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By sGC stimulator 

Figure 67: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By sGC stimulator 

Figure 68: Western Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2018-2028

Figure 69: Western Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2018-2028 

Figure 70: Western Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2028  

Figure 71: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2013–2017

Figure 72: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 73: Russia Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 74: Russia Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 75: Poland Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 76: Poland Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 77: Rest of Eastern Europe Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 78: Rest of Eastern Europe Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 79: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By Vasodilators

Figure 80: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By Vasodilators 

Figure 81: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By ERA

Figure 82: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By ERA

Figure 83: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By PDE-5

Figure 84: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By PDE-5

Figure 85: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By sGC stimulator 

Figure 86: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By sGC stimulator 

Figure 87: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2018-2028

Figure 88: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2018-2028 

Figure 89: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2028  

Figure 90: APECJ Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2013–2017

Figure 91: APECJ Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 92: India Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 93: India Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 94: Australia & New Zealand Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 95: Australia & New Zealand Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 96: ASEAN Countries Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 97: ASEAN Countries Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 98: Rest of APECJ Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 99: Rest of APECJ Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 100: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By Vasodilators

Figure 101: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By Vasodilators 

Figure 102: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By ERA

Figure 103: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By ERA

Figure 104: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By PDE-5

Figure 105: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By PDE-5

Figure 106: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By sGC stimulator 

Figure 107: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By sGC stimulator 

Figure 108: APECJ Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2018-2028

Figure 109: APECJ Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2018-2028 

Figure 110: APECJ Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2028  

Figure 111: China Pulmonary Arterial Hypertension Treatment Market Split By Drug Class (2018)

Figure 112: China Pulmonary Arterial Hypertension Treatment Market Split By Distribution Channel (2018)

Figure 113: China Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2013–2017

Figure 114: China Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 115: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By Vasodilators

Figure 116: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By Vasodilators 

Figure 117: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By ERA

Figure 118: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By ERA

Figure 119: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By PDE-5

Figure 120: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By PDE-5

Figure 121: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By sGC stimulator 

Figure 122: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By sGC stimulator 

Figure 123: China Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2018-2028 

Figure 124: China Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2028  

Figure 125: Japan Pulmonary Arterial Hypertension Treatment Market Split By Drug Class (2018)

Figure 126: Japan Pulmonary Arterial Hypertension Treatment Market Split By Distribution Channel (2018)

Figure 127: Japan Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2013–2017

Figure 128: Japan Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 129: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By Vasodilators

Figure 130: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By Vasodilators 

Figure 131: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By ERA

Figure 132: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By ERA

Figure 133: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By PDE-5

Figure 134: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By PDE-5

Figure 135: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By sGC stimulator 

Figure 136: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By sGC stimulator 

Figure 137: Japan Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2018-2028 

Figure 138: Japan Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2028  

Figure 139: MEA Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2013–2017

Figure 140: MEA Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2018–2028

Figure 141: GCC Countries Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 142: GCC Countries Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 143: South Africa Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 144: South Africa Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 145: Rest of MEA Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2013–2017

Figure 146: Rest of MEA Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2018-2028

Figure 147: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By Vasodilators

Figure 148: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By Vasodilators 

Figure 149: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By ERA

Figure 150: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By ERA

Figure 151: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2013–2017, By PDE-5

Figure 152: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2018-2028, By PDE-5

Figure 153: MEA Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2018-2028

Figure 154: MEA Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2018-2028 

Figure 155: MEA Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2028  

Figure 156: Global Pulmonary Arterial Hypertension Treatment Market Company Share Analysis (2017)

Figure 157: Global Pulmonary Arterial Hypertension Treatment Industry Structure 

Figure 158: Global Pulmonary Arterial Hypertension Treatment Market Share, By Tier (2017)

Figure 159: Global Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Region, 2018–2028 

Figure 160: Global Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Type, 2018–2028 

Figure 161: Global Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2018–2028 

Figure 162: Global Pulmonary Arterial Hypertension Treatment Market Value Analysis and Forecast, 2016–2028 (US$ Mn)

Figure 163: Global Pulmonary Arterial Hypertension Treatment Market Absolute $ Opportunity (US$ Mn), 2016–2028